However, it is important to understand that IGF-1 LR3 is not FDA-approved for bodybuilding or aesthetic enhancement
As a result, healthcare providers face difficulties in prescribing these medications, which can hinder overall market growth and patient outcomes in obesity management
But coverage is more nuanced than a yes-no decision. Insurers may respond to lower GLP-1 prices by increasing restrictions, which are already stringent, as Klebanoff showed in two studies with LDI Senior Fellows Jalpa Doshi and Judith Long, and colleagues
The effect often eases once the dose drops
You cannot use a GLP-1 agonist if you do not fit into the criteria for the prescription and are just trying to shed a few pounds
However, simultaneous initiation is acceptable in motivated patients requiring rapid glycaemic improvement